{"id":"sibutramine-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin component)"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sibutramine acts as a norepinephrine and serotonin reuptake inhibitor, increasing satiety and reducing food intake. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, they target weight loss and glycemic control through complementary mechanisms in obesity and type 2 diabetes management.","oneSentence":"Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:37.829Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity with or without type 2 diabetes mellitus"},{"name":"Weight management in patients with metabolic syndrome"}]},"trialDetails":[{"nctId":"NCT05821543","phase":"PHASE4","title":"Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-07-03","conditions":"Obesity","enrollment":240},{"nctId":"NCT00941382","phase":"PHASE3","title":"Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients","status":"UNKNOWN","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2008-11","conditions":"Obesity","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["combination therapy"],"phase":"phase_3","status":"active","brandName":"Sibutramine-Metformin","genericName":"Sibutramine-Metformin","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism. Used for Obesity with or without type 2 diabetes mellitus, Weight management in patients with metabolic syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}